公开(公告)号：US20180185333A1

公开(公告)日：2018-07-05

申请号：US15908504

申请日：2018-02-28

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Keith B. Marschke ,  Lin Zhi

IPC: A61K31/4045 ,  G01N33/50 ,  A61N5/10 ,  A61K45/06 ,  A61K31/454 ,  A61K31/4155 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4015 ,  A61K31/40

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

公开(公告)号：US20160022638A1

公开(公告)日：2016-01-28

申请号：US14775587

申请日：2014-03-10

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Keith B. Marschke ,  Lin Zhi

IPC: A61K31/4045 ,  G01N33/50 ,  A61N5/10 ,  A61K45/06

CPC classification number: A61K31/4045 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/454 ,  A61K45/06 ,  A61N5/10 ,  G01N33/5011

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

Abstract translation: 一些实施方案包括用于治疗，预防，逆转，停止或减缓癌症进展的方法，包括向有需要的受试者施用有效量的一种或多种化学治疗剂或其药学上可接受的盐或药物组合物， 其中至少一种化学治疗剂是细胞毒性粒细胞集落刺激因子受体（GCFR）调节剂。 还公开了用于治疗，预防，逆转，停止或减缓造血障碍进展的方法，包括向有需要的受试者施用治疗有效的细胞毒性量的GCFR调节剂。

公开(公告)号：US10420748B2

公开(公告)日：2019-09-24

申请号：US15908504

申请日：2018-02-28

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Keith B. Marschke ,  Lin Zhi

IPC: A61K31/4045 ,  A61K31/4152 ,  A61K45/06 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/454 ,  A61N5/10 ,  G01N33/50 ,  A61K31/40 ,  A61K31/4015

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.